Theravance Inc - Net Worth and Insider Trading
Theravance Inc Net Worth
The estimated net worth of Theravance Inc is at least $209 Million dollars as of 2024-11-05. Theravance Inc is the 10% Owner of Entasis Therapeutics Holdings Inc and owns about 69,615,035 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $152 Million. Theravance Inc is also the Director, 10% Owner of Armata Pharmaceuticals Inc and owns about 25,076,769 shares of Armata Pharmaceuticals Inc (ARMP) stock worth over $57 Million. Details can be seen in Theravance Inc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Theravance Inc has not made any transactions after 2022-07-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Theravance Inc
Theravance Inc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Theravance Inc owns 3 companies in total, including Entasis Therapeutics Holdings Inc (ETTX) , Armata Pharmaceuticals Inc (ARMP) , and Theravance Biopharma Inc (TBPH) .
Click here to see the complete history of Theravance Inc’s form 4 insider trades.
Insider Ownership Summary of Theravance Inc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ETTX | Entasis Therapeutics Holdings Inc | 2022-07-11 | 10 percent owner |
| ARMP | Armata Pharmaceuticals Inc | 2022-03-31 | director & 10 percent owner |
| TBPH | Theravance Biopharma Inc | 2014-05-14 | 10 percent owner |
Theravance Inc Latest Holdings Summary
Theravance Inc currently owns a total of 2 stocks. Among these stocks, Theravance Inc owns 69,615,035 shares of Entasis Therapeutics Holdings Inc (ETTX) as of July 11, 2022, with a value of $152 Million and a weighting of 72.79%. Theravance Inc also owns 25,076,769 shares of Armata Pharmaceuticals Inc (ARMP) as of March 31, 2022, with a value of $57 Million and a weighting of 27.21%.
Latest Holdings of Theravance Inc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ETTX | Entasis Therapeutics Holdings Inc | 2022-07-11 | 69,615,035 | 2.19 | 152,456,927 |
| ARMP | Armata Pharmaceuticals Inc | 2022-03-31 | 25,076,769 | 2.27 | 56,986,958 |
Holding Weightings of Theravance Inc
Theravance Inc Form 4 Trading Tracker
According to the SEC Form 4 filings, Theravance Inc has made a total of 5 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Entasis Therapeutics Holdings Inc is the acquisition of 19,270,476 shares on July 11, 2022, which cost Theravance Inc around $42 Million.
According to the SEC Form 4 filings, Theravance Inc has made a total of 6 transactions in Armata Pharmaceuticals Inc (ARMP) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in Armata Pharmaceuticals Inc is the acquisition of 5,385,208 shares on March 31, 2022, which cost Theravance Inc around $27 Million.
Insider Trading History of Theravance Inc
- 1
Theravance Inc Trading Performance
GuruFocus tracks the stock performance after each of Theravance Inc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Theravance Inc is 3.06%. GuruFocus also compares Theravance Inc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Theravance Inc within 3 months outperforms 4 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Theravance Inc's insider trading performs compared to the benchmark.
Performance of Theravance Inc
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 4.48 | | | | | |
| Relative Return to S&P 500(%) | 3.69 | | | | | |
Theravance Inc Ownership Network
Ownership Network List of Theravance Inc
Ownership Network Relation of Theravance Inc
Theravance Inc Owned Company Details
What does Entasis Therapeutics Holdings Inc do?
Who are the key executives at Entasis Therapeutics Holdings Inc?
Theravance Inc is the 10 percent owner of Entasis Therapeutics Holdings Inc. Other key executives at Entasis Therapeutics Holdings Inc include VP & Principal Fin & Acct Off Kristie Ann Wagner , General Counsel Elizabeth M Keiley , and See Remarks Matthew Ronsheim .
Entasis Therapeutics Holdings Inc (ETTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Entasis Therapeutics Holdings Inc (ETTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Entasis Therapeutics Holdings Inc (ETTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Entasis Therapeutics Holdings Inc (ETTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Entasis Therapeutics Holdings Inc Insider Transactions
Theravance Inc Mailing Address
Above is the net worth, insider trading, and ownership report for Theravance Inc. You might contact Theravance Inc via mailing address: 1350 Old Bayshore Highway, Suite 400, Burlingame Ca 94010.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
